Immediate Impact
73 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of Thomas McFarlane being referenced
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
2018
Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Thomas McFarlane | 121 | 53 | 102 | 19 | 284 | |
| James Trotter | 128 | 32 | 123 | 13 | 302 | |
| Faïza Khemissa | 148 | 59 | 46 | 23 | 250 | |
| Jiaze Hong | 114 | 69 | 72 | 26 | 303 | |
| Alessandra Mele | 56 | 35 | 126 | 28 | 318 | |
| Raquel Molina | 151 | 62 | 42 | 24 | 303 | |
| Christine Yu | 96 | 71 | 78 | 26 | 300 | |
| De-Rong Xie | 154 | 93 | 76 | 24 | 284 | |
| Zhiyong Liu | 84 | 75 | 80 | 22 | 308 | |
| Christopher Hocking | 170 | 178 | 84 | 15 | 320 | |
| Danielle Armas | 52 | 69 | 47 | 17 | 295 |
All Works
Login with ORCID to disown or claim papers
Loading papers...